Kedudukan dalam Saham
#42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Harga Saham
$0.00023723
Disegerakkan terakhir: 2024-08-26
Perubahan (1 hari)
111.67%
Perubahan (1 tahun)
0.00%
Perdagangan Pharnext S.A. (ALPHA)
Harga ALPHA dengan permodalan pasaran b
Modal pasaran bagi Pharnext S.A.(ALPHA)
Modal Pasaran: $1.41K
Sehingga August 2026, Pharnext S.A. mempunyai modal pasaran sebanyak $1.41K. Ini menjadikan Pharnext S.A. syarikat ke-42432nd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Pharnext S.A. dari 2023 hingga 2026
ALPHA berbanding dengan 5 teratas yang paling popular stocks
| Harga ALPHA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.426T
|
+384,416,569,226.37%
|
|
|
|
|
$4.424T
|
+313,428,893,892.81%
|
|
|
|
|
$4.157T
|
+294,524,702,274.60%
|
|
|
|
|
$3.655T
|
+258,961,252,486.21%
|
|
|
|
|
$2.892T
|
+204,876,716,734.66%
|
